In the age of innovation, domestic pharmaceutical companies prefer this track

Since this year, a number of pharmaceutical companies, including Watson Pharmaceuticals, Yifan Pharmaceuticals, Guangshengtang and Health Yuan, have released information on organizational restructuring.
Russion Pharmaceuticals, such as Watson Pharmaceuticals, said on the interactive platform some time ago that the company has companies in the innovation drug sector, such as the introduction of the first scientific officer, the establishment of innovative pharmaceutical business unit, the construction of innovative pharmaceutical laboratories, the creation of innovative pharmaceutical talent team, etc., has been partially completed or is in progress, the follow-up specific projects will be carried out in an orderly manner as planned.
Innovating era, domestic pharmaceutical companies prefer this track (photo source: pharmaceutical network) industry insiders believe that, with China's pharmaceutical innovation environment continues to improve, the profit margins of generic drugs gradually narrowed, well-known pharmaceutical companies have adjusted the organizational structure, the original intention is to better adapt to the needs of innovation transformation, help improve the corporate governance structure, improve the company's operational efficiency, optimize management processes.
, under the tide of innovation, we can see that the innovation drive of enterprises is enhanced, and the research and development investment of pharmaceutical companies is also increasing.
data show that as of September 14, 2020, there were 347 pharmaceutical and biological listed companies in A-shares.
, 347 pharmaceutical and biological listed companies invested a total of 23.832 billion yuan in research and development in the first half of the year, up 16.8% YoY, with an average investment of 669 million yuan.
from the major pharmaceutical companies research and development investment can be clearly found that innovation has become the only way for the development of pharmaceutical companies.
it is worth noting that while pharmaceutical companies are investing more in research and development, many have chosen the same innovation track.
, the new anti-tumor drug is a hot track chosen by many pharmaceutical companies in recent years.
incomplete statistics, as of September 10, 2020, a total of 9 new domestic anti-tumor drugs were approved for market, MNC new drugs approved 10 varieties.
, the growth rate was more pronounced, with domestic new drugs up 125% year-on-year and MNC down 9%.
Specifically, in 2020, Kadcyla, the country's first ADC drug, was approved; From the proportion of domestic new drugs has been close to 50%, and the growth rate is still continuing in the background, China's pharmaceutical enterprises have a considerable strength of new drug innovation, in the domestic market has gradually been able to compete with foreign investment, the future or will achieve beyond.
in fact, in addition to the number, growth rate is rising, domestic enterprises in the layout of anti-tumor innovative drugs also began to show the characteristics of a hundred flowers, Hengrui, as always, "strong", whether in the overall layout or anti-tumor field layout is very extensive, and the development progress and high production of innovative drugs, is a well-deserved innovation drug leading enterprises.
And other enterprises also have their own advantages, such as Beda deep in lung cancer small molecule targeted drugs, Junshi is the first anti-PD-1 monoclonal antibody NMPA listed approval of the Chinese company, is one of the few companies with the potential to develop the world's first drug;
the current development situation, the industry expects that the future of domestic innovative pharmaceutical companies may present a "super strong" competitive situation.